To evaluate the diagnostic accuracy of artificial intelligence (AI) assisted radiologists and standard double-reading in real-world clinical settings for rib fractures (RFs) detection on CT images. This study included 243 consecutive chest trauma patients (mean age, 58.1 years; female, 166) with rib CT scans. All CT scans were interpreted by two radiologists. The CT images were re-evaluated by primary readers with AI assistance in a blinded manner. Reference standards were established by two musculoskeletal radiologists. The re-evaluation results were then compared with those from the initial double-reading. The primary analysis focused on demonstrate superiority of AI-assisted sensitivity and the noninferiority of specificity at patient level, compared to standard double-reading. Secondary endpoints were at the rib and lesion levels. Stand-alone AI performance was also assessed. The influence of patient characteristics, report time, and RF features on the performance of AI and radiologists was investigated. At patient level, AI-assisted radiologists significantly improved sensitivity by 25.0% (95% CI: 10.5, 39.5; P < 0.001 for superiority), compared to double-reading, from 69.2% to 94.2%. And, the specificity of AI-assisted diagnosis (100%) was noninferior to double-reading (98.2%) with a difference of 1.8% (95% CI: -3.8, 7.4; P = 0.999 for noninferiority). The diagnostic accuracy of both radiologists and AI was influenced by patient gender, rib number, fracture location, and fracture type. Radiologist performance was affected by report time, whereas AI's diagnostic accuracy was influenced by patient age and the side of the rib involved. AI-assisted additional-reader workflow might be a feasible strategy to instead of traditional double-reading, potentially offering higher sensitivity and specificity compared to standard double-reading in real-word clinical practice.
Download full-text PDF |
Source |
---|---|
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0316732 | PLOS |
Age Ageing
January 2025
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: A mobile cognition scale for community screening in cognitive impairment with rigorous validation is in paucity. We aimed to develop a digital scale that overcame low education for community screening for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD.
Methods: A mobile cognitive self-assessment scale (CogSAS) was designed through the Delphi process, which is feasible for the older population with low education.
Comput Biol Med
January 2025
Emerging Technologies Research Lab (ETRL), College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia; Department of Computer Science, College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia. Electronic address:
- Brain tumors (BT), both benign and malignant, pose a substantial impact on human health and need precise and early detection for successful treatment. Analysing magnetic resonance imaging (MRI) image is a common method for BT diagnosis and segmentation, yet misdiagnoses yield effective medical responses, impacting patient survival rates. Recent technological advancements have popularized deep learning-based medical image analysis, leveraging transfer learning to reuse pre-trained models for various applications.
View Article and Find Full Text PDFObjectives: To determine and compare the diagnostic accuracy of imaging tests for the prediction of RA progression in people with inflammatory joint pain or CSA.
Methods: We searched MEDLINE, Embase and Web of Science from 1987 to March 2024. Studies evaluating any imaging tests in participants with inflammatory joint pain or CSA, without clinical synovitis were eligible.
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFJ Mol Neurosci
January 2025
Lanzhou University Second Hospital, The Second Medical College of Lanzhou University, Cuiyingmen No.82, Chengguan District, Lanzhou, 730030, China.
Ischemic stroke leads to permanent damage to the affected brain tissue, with strict time constraints for effective treatment. Predictive biomarkers demonstrate great potential in the clinical diagnosis of ischemic stroke, significantly enhancing the accuracy of early identification, thereby enabling clinicians to intervene promptly and reduce patient disability and mortality rates. Furthermore, the application of predictive biomarkers facilitates the development of personalized treatment plans tailored to the specific conditions of individual patients, optimizing treatment outcomes and improving prognoses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!